Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-9623087-B2
Application number	US-201214361787-A
Country	US
Kind code	B2
Filing date	Nov 30, 2012
Priority date	Nov 30, 2011
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

First claim

What is claimed is:

1. A medical device comprising:
an array of microneedles; and
a coating on or within at least a portion of the microneedles, wherein the coating comprises:
a peptide therapeutic agent; and
an amino acid,

wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and
wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

2. The medical device of claim 1 , wherein the coating is substantially free of sorbitol.

3. The medical device of claim 1 , wherein the amino acid is histidine.

4. The medical device of claim 3 , wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 2:1.

5. The medical device of claim 4 , wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 1.5:1.

6. The medical device of claim 3 , wherein the histidine stabilizes the peptide therapeutic agent in the coating.

7. The medical device of claim 1 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is less than 2:1.

8. The medical device of claim 7 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is in a range from 0.5:1 to 55:1.

9. The medical device of claim 1 , wherein the amino acid is histidine, arginine, or lysine.

10. The medical device of claim 1 , wherein the amino acid is present in the coating in a range from 0.1 to 15 percent by weight, based on the total weight of the coating.

11. The medical device of claim 1 , wherein the array of microneedles comprises a dissolvable matrix material, or wherein at least some of the microneedles are hollow.

12. A method of making a medical device comprising microneedles, the method comprising:
providing an aqueous composition comprising a peptide therapeutic agent, an amino acid, and a buffer, wherein the peptide therapeutic agent and the amino acid both have a net positive charge in the aqueous composition;
contacting the microneedles with the aqueous composition; and
volatilizing a portion of the aqueous composition to provide a coating on at least a portion of the microneedles, wherein the coating comprises at least the peptide therapeutic agent and the amino acid, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

13. The method of claim 12 , wherein the aqueous composition has a pH in a range from 3 to 11.

14. The method of claim 12 , wherein the amino acid is histidine, and wherein the molar ratio of the histidine to the peptide therapeutic agent in the aqueous composition is less than 2:1.

15. The method of claim 12 , wherein the buffer comprises phosphate, acetate, citrate, or tris(hydroxymethyl)aminomethane.

16. The method of claim 12 , wherein the amino acid is histidine, arginine, or lysine.

17. The method of claim 12 , wherein the aqueous composition or the coating is substantially free of sorbitol.

18. A method of stabilizing a peptide therapeutic agent on or within an array of microneedles, the method comprising incorporating the peptide therapeutic agent and an amino acid on or within the array of microneedles, wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

Assignees

• 3M Innovative Properties Co

Inventors

• Zhang Ying
• Fenn Percy T
• Johnson Peter R

Classifications

• A61L2300/252

  Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines · CPC title

• A61K38/225

  Calcitonin gene related peptide · CPC title

• A61M37/0015

  by using microneedles · CPC title

• A61K38/29 Primary

  Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title